MCM
AZN icon

Moore Capital Management’s AstraZeneca AZN Stock Holding History

Moore Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100,000
Closed -$13.5M – 446
2023
Q3 		$13.5M Buy
+100,000
New +$13.7M 0.25% 75

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Moore Capital Management's AZN Position: Q4 2023 in Review

Moore Capital Management sold out of AstraZeneca (AZN) in Q4 2023, closing a stake of 25,000 shares — an estimated $3.39M sold.

Moore Capital Management first reported a position in AZN in Q2 2014 and held it in 4 quarters. The position peaked at $24M in Q4 2021. 1,131 funds tracked by Wall St. Rank hold AZN as of Q4 2023.

  • Moore Capital Management reported no remaining AstraZeneca position as of Q4 2023 after selling out during the quarter.
  • Moore Capital Management sold 25,000 AstraZeneca shares in Q4 2023, an estimated $3.39M.
  • Moore Capital Management first reported a position in AstraZeneca in Q2 2014 and held it in 4 quarters.
  • Moore Capital Management's AstraZeneca position peaked at $24M in Q4 2021.
  • 1,131 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2023.

Based on Moore Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.